The short version of peptide agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Franz Joseph died in the Schönbrunn Palace on the evening of 21 November 1916, at the age of 86. His final words to his valet were: "Tomorrow morning, at half past three." Although sick, he was determined to rise at his usual time. His death was a result of developing pneumonia of the right lung several days after catching a cold while walking in Schönbrunn Park with King Ludwig III of Bavaria. He was succeeded by his grandnephew Charles I & IV, who reigned until the collapse of the empire following its defeat at the end of the First World War in 1918. He is buried in the Imperial Crypt in Vienna.
==== MeSH D12.776.964.700.750 – retroviridae proteins, oncogenic ==== MeSH D12.776.964.700.750.320 – fusion proteins, gag-onc MeSH D12.776.964.700.750.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.700.750.470 – gene products, rex MeSH D12.776.964.700.750.480 – gene products, tax (gene) MeSH D12.776.964.700.750.650 – oncogene protein gp140(v-fms) MeSH D12.776.964.700.750.710 – oncogene protein p21(ras) MeSH D12.776.964.700.750.750 – oncogene protein p55(v-myc) MeSH D12.776.964.700.750.760 – oncogene protein pp60(v-src) MeSH D12.776.964.700.750.817 – oncogene protein v-maf MeSH D12.776.964.700.750.875 – oncogene proteins v-abl MeSH D12.776.964.700.750.882 – oncogene proteins v-erba MeSH D12.776.964.700.750.883 – oncogene proteins v-erbb MeSH D12.776.964.700.750.887 – oncogene proteins v-fos MeSH D12.776.964.700.750.900 – oncogene proteins v-mos MeSH D12.776.964.700.750.903 – oncogene proteins v-myb MeSH D12.776.964.700.750.920 – oncogene proteins v-raf MeSH D12.776.964.700.750.925 – oncogene proteins v-rel MeSH D12.776.964.700.750.935 – oncogene proteins v-sis
=== Available forms === Finasteride (brand names Proscar, Propecia) inhibits the function of two of the isoenzymes (types 2 and 3) of 5α-reductase. It decreases circulating DHT levels by up to about 70%. Dutasteride (brand name Avodart) inhibits all three 5α-reductase isoenzymes and can decrease DHT levels by 95%. It can also reduce DHT levels in the prostate by 97 to 99% in men with prostate cancer. Epristeride (brand names Aipuliete, Chuanliu) is marketed in China for the treatment of benign prostatic hyperplasia. However, it can only decrease circulating DHT levels by about 25 to 54%. Alfatradiol (brand names Ell-Cranell Alpha, Pantostin) is a topical 5-ARI used to treat pattern hair loss in Europe.
Sources: en.wikipedia.org
Besides inhibiting human acetylcholinesterase (although to a lesser degree than the insect enzyme), carbamate insecticides also target human melatonin receptors. The human health effects of carbamates are well documented in the list of known endocrine disruptor compounds. Clinical effects of carbamate exposure can vary from slightly toxic to highly toxic depending on a variety of factors including such as dose and route of exposure with ingestion and inhalation resulting in the most rapid clinical effects. These clinical manifestations of carbamate intoxication are muscarinic signs, nicotinic signs, and in rare cases central nervous system signs.
=== Scientific cores === The bioinformatics core contributes bioinformatic analysis by collecting and curating complete sequence data sets, generating sequence similarity networks, and classification of superfamily members into subgroups and families for subsequent annotation transfer and evaluation as targets for functional characterization. The protein core develops cloning, expression, and protein purification strategies for the enzymes targeted for study. The structure core fulfills the structural biology component for EFI by providing high resolution structures of targeted enzymes. The computation core performs in silico docking to generate rank-ordered lists of predicted substrates for targeted enzymes using both experimentally determined and/or homology modeled protein structures. The microbiology core examines in vivo functions using genetic techniques and metabolomics to complement in vitro functions determined by the Bridging Projects. The data and dissemination core maintains a public database for experimental data (EFI-DB).
1983 – 1st Pump MiniMed 502 (Eli Lilly makes synthetic insulin) 1985 – MiniMed 504 Insulin Pump 1992 – Launch Of MiniMed 506 Insulin Pump 1996 – Introduction of MiniMed 507 Pump 1999 – Launch of the Model 507C 1999 – Introduction of MiniMed 508 Insulin Pump 2002 – Inauguration of the MiniMed Paradigm 511 2003 – 1st Wireless MiniMed Paradigm 512/712 (followed by 515/715) 2006 – MiniMed Paradigm REAL-Time 522/722 2010 – MiniMed Paradigm REAL-Time Revel 523/723
Sources: en.wikipedia.org
A carboxypeptidase (EC number 3.4.16 - 3.4.18) is a protease enzyme that hydrolyzes (cleaves) a peptide bond at the carboxy-terminal (C-terminal) end of a protein or peptide. This is in contrast to an aminopeptidases, which cleave peptide bonds at the N-terminus of proteins. Humans, animals, bacteria and plants contain several types of carboxypeptidases that have diverse functions ranging from catabolism to protein maturation. At least two mechanisms have been discussed.
Historically, slaves in the Arab World came from many different regions, including Sub-Saharan Africa (mainly Zanj), the Caucasus (mainly Circassians), Central Asia (mainly Tartars), and Central and Eastern Europe (mainly Slavs Saqaliba). These slaves were trafficked to the Arab world from Africa via the Trans-Saharan slave trade, the Baqt treaty, the Red Sea slave trade and the Indian Ocean slave trade; from Asia via the Bukhara slave trade; and from Europe via the Prague slave trade, the Venetian slave trade and the Barbary slave trade, respectively.
It is quite surprising that the use of pepper has come so much into fashion, seeing that in other substances which we use, it is sometimes their sweetness, and sometimes their appearance that has attracted our notice; whereas, pepper has nothing in it that can plead as a recommendation to either fruit or berry, its only desirable quality being a certain pungency; and yet it is for this that we import it all the way from India! Who was the first to make trial of it as an article of food? and who, I wonder, was the man that was not content to prepare himself by hunger only for the satisfying of a greedy appetite? He does not state whether the 50 million was the actual amount of money which found its way to India or the total retail cost of the items in Rome; elsewhere, he cites a figure of 100 million sesterces.
=== Workflow === Long-wavelength UV and SDA reagents are first supplied to living cells to crosslink protein residues with RNA by forming amide bonds between amine groups of lysine (or arginine) residues and succinimidyl esters. Next, cells containing crosslinked RNPs are lysed and the RNA-bound proteins are digested into peptide adducts. MaP reverse transcription is then performed to label the protein-RNA binding sites through peptide adduct-induced mutations. Sequencing of the mutation-containing cDNA product will reveal the mutation sites (or RNP-MaP sites) and the correlations between the RNP-MaP sites are computationally determined using 3-nucleotide windows.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.